Health Care/Hospital
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum
ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...
2023-12-20 20:00
1277
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload pl...
2023-12-20 09:00
1412
Standigm named as a Tech Innovator in Generative AI in Drug Discovery use case
SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm
2023-12-19 22:00
1302
New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA
SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injec...
2023-12-19 20:00
1213
Tianjin's Youthful Energy Sparks Citywide Revival
TIANJIN, China, Dec. 19, 2023 /PRNewswire/ -- A report from China Daily: Tianjin, a city in North China, is undergoing a dynamic transformation driven by its vibrant young people. China Daily Potside Chats hosts, Nathan and Stephanie, recently explored the city's cutting-edge developments led by ...
2023-12-19 15:44
1392
Biorithm Secures $3.5 Million in Series A Funding to Advance Maternal Care Worldwide
New funds to fortify US market entry and growth strategy, as well as advance breakthrough research CAMBRIDGE, Mass., Dec. 18, 2023 /PRNewswire/ -- Biorithm, a global women's health medtech, has closed$3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital. With a ...
2023-12-18 22:00
1261
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Highlights: * Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures * Improvements were consistently seen across clinically important aspects of Phelan-McDermid syndrome, including communication, behaviour, cognition/learning and socialis...
2023-12-18 19:00
1089
NUS researchers develop an innovative and flexible method to study immune cell capabilities
This simple and efficient method can directly identify and sort immune cells involved in cell-mediated cytotoxicity SINGAPORE, Dec. 17, 2023 /PRNewswire/ -- Our body's immune system is a complex network of organs, cells, and proteins that work in synchrony to protect our bodies against infection...
2023-12-18 14:47
1283
GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...
2023-12-18 09:49
1278
GeneQuantum and BioMap establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics
SUZHOU, China, Dec. 17, 2023 /PRNewswire/ -- Recently, GeneQuantum Healthcare (GQ), a global leader in ADC new drug development focused on innovative bioconjugation technologies, and BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, announced that the...
2023-12-18 09:43
1184
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's firstin vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardio...
2023-12-17 23:15
1343
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over$100M by issuing 8 million new shares. The new funding will enable Caliway to advance the clinical development of its lead pipeline CBL-514, a sma...
2023-12-16 15:47
1808
Ubie Won the "Best with AI" in Google Play Best of 2023 (Japan)
NEW YORK, Dec. 15, 2023 /PRNewswire/ -- Ubie, Inc., headquartered at 1460
Broadway,New York, NY 10036 and led by CEO Kota Kubo, proudly announces that
the Japanese version of Ubie's AI Symptom Checker (https://ubie.app/
2023-12-16 00:00
2008
SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care
SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests SHENZHEN, China, Dec. 15, 2023 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early ...
2023-12-15 21:00
1304
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
2023-12-15 21:00
1391
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...
2023-12-15 11:14
1632
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...
2023-12-15 07:30
1348
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisioning completion by Q2 2024 SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
2023-12-14 22:05
1325
China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on December 13, 2023, t...
2023-12-14 21:30
3319
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT
Keynote speaker Peter Marks to Deliver Address Free Early Bird Registration Closing Soon NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dre...
2023-12-14 20:34
2196
Week's Top Stories
Most Reposted
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 315 media titles]
2024-05-15 12:00
Thousands set to gather in Singapore for Rotary's international convention, the Garden City's largest association event post-pandemic
[Picked up by 289 media titles]
2024-05-09 11:00
i2Cool Attracts Close to HKD100 Million in Series A Financing to Propel the Development of Green and Energy-Efficient Radiant Cooling Solutions
[Picked up by 283 media titles]
2024-05-09 10:50
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
[Picked up by 272 media titles]
2024-05-10 15:20
Where does China's production capacity come from?
[Picked up by 258 media titles]
2024-05-10 12:01Most Read
Thousands set to gather in Singapore for Rotary's international convention, the Garden City's largest association event post-pandemic
2024-05-09 11:00
12599
Cision's 2024 State of the Media Report: Journalists Battle Misinformation, Embrace Data, and Seek PR Partnership
2024-05-09 10:00
8139
i2Cool Attracts Close to HKD100 Million in Series A Financing to Propel the Development of Green and Energy-Efficient Radiant Cooling Solutions
2024-05-09 10:50
7880
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
7644
